Bioluminescence Ventures, a San Francisco, CA-based biotech venture firm investing in next-generation medicines, has emerged from stealth with $477M in assets under management across two funds.
The firm is supported by an U.S. and multinational institutional Limited Partners.
Led by Founding and Managing Partner Kouki Harasaki, Ph.D., Bioluminescence is a biotechnology venture capital firm investing in companies translating transformative science into next-generation medicines that will impact patients. The firm focuses investments on four areas: Breakthrough Biology, Drug Discovery Platforms, Genetic Medicines Platforms, and Computational Biology Platforms.
Bioluminescence Ventures’ portfolio currently consists of multiple companies including:
- Ensoma
- Nido Biosciences
- ReCode Therapeutics
- SURGE Therapeutics
The firm prefers to lead rounds – working closely with leadership teams to complete diligence, negotiate equitable terms, secure the syndicate, and close the round with speed and efficiency.
FinSMEs
01/11/2023